Director/PDMR share purchase
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 6 December 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that yesterday James McCullough, Chief Executive Officer, bought 53,300 ordinary shares of £0.0025 each ("Ordinary Shares") in the Company at a price of £0.075 per Ordinary Share.
Following this transaction, James McCullough is interested in 3,217,096 Ordinary Shares representing 0.55% of the issued share capital of the Company.
In addition, Chris Scott, Chief Operating Officer of Renalytix, whilst not a Board Director or a PDMR, has disclosed to the Company that on 4 December he purchased 25,000 Ordinary Shares at a price of £0.075.
| a) | Name | James McCullough |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | Renalytix plc |
| b) | LEI | 213800NTOH3FK3WER551 |
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.0025 each |
| Identification code | GB00BYWL4Y04 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| £0.075 | 53,300 | |
| d) | Aggregated information | |
| - Aggregated volume | 53,300 | |
| - Price | £0.075 | |
| e) | Date of the transaction | 5 December 2024 |
| f) | Place of the transaction | London Stock Exchange, AIM |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.